The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation

Kazuteru Ohashi, Juichi Tanabe, Reiko Watanabe, Takeshi Tanaka, Hisashi Sakamaki, Atsuo Maruta, Shinichiro Okamoto, Nobuyuki Aotsuka, Kenji Saito, Miki Nishimura, Hakumei Oh, Michio Matsuzaki, Satoshi Takahashi, Shuji Yonekura

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Hepatic veno-occlusive disease (VOD) is a common transplant-related complication of stem cell transplantation. There is no safe and proven therapy for established VOD, and attempts have focused on its prevention. Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced the incidence of VOD. To confirm the preventive effect of UDCA on VOD, we conducted a prospective, unblinded randomized, multicenter study of UDCA involving 132 patients who underwent stern cell transplantation for a variety of disorders. Sixty-seven patients were assigned to the UDCA-treated group, and 65 patients were assigned to the control group. The clinical characteristics of the two groups were similar with respect to primary diagnosis, age, sex, and baseline organ function. The preparative regimen and GVHD prophylaxis did not differ significantly between the two groups. UDCA was highly effective in preventing VOD, which occurred in only 3.0% in the UDCA-treated group, as opposed to 18.5% in the control group (P = 0.0043). There were no adverse effects attributable to UDCA. The initial promising report of a prophylactic effect of UDCA on VOD after stern cell transplantation was confirmed in this prospective study. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalAmerican Journal of Hematology
Volume64
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Hepatic Veno-Occlusive Disease
Ursodeoxycholic Acid
Stem Cell Transplantation
Cell Transplantation
Control Groups
Multicenter Studies
Prospective Studies
Transplants

Keywords

  • Hepatic VOD
  • Prophylaxis
  • Stem cell transplantation
  • Ursodeoxycholic acid (UDCA)

ASJC Scopus subject areas

  • Hematology

Cite this

The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. / Ohashi, Kazuteru; Tanabe, Juichi; Watanabe, Reiko; Tanaka, Takeshi; Sakamaki, Hisashi; Maruta, Atsuo; Okamoto, Shinichiro; Aotsuka, Nobuyuki; Saito, Kenji; Nishimura, Miki; Oh, Hakumei; Matsuzaki, Michio; Takahashi, Satoshi; Yonekura, Shuji.

In: American Journal of Hematology, Vol. 64, No. 1, 2000, p. 32-38.

Research output: Contribution to journalArticle

Ohashi, K, Tanabe, J, Watanabe, R, Tanaka, T, Sakamaki, H, Maruta, A, Okamoto, S, Aotsuka, N, Saito, K, Nishimura, M, Oh, H, Matsuzaki, M, Takahashi, S & Yonekura, S 2000, 'The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation', American Journal of Hematology, vol. 64, no. 1, pp. 32-38. https://doi.org/10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N
Ohashi, Kazuteru ; Tanabe, Juichi ; Watanabe, Reiko ; Tanaka, Takeshi ; Sakamaki, Hisashi ; Maruta, Atsuo ; Okamoto, Shinichiro ; Aotsuka, Nobuyuki ; Saito, Kenji ; Nishimura, Miki ; Oh, Hakumei ; Matsuzaki, Michio ; Takahashi, Satoshi ; Yonekura, Shuji. / The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. In: American Journal of Hematology. 2000 ; Vol. 64, No. 1. pp. 32-38.
@article{e654f4956fd445689fc60ca764612645,
title = "The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation",
abstract = "Hepatic veno-occlusive disease (VOD) is a common transplant-related complication of stem cell transplantation. There is no safe and proven therapy for established VOD, and attempts have focused on its prevention. Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced the incidence of VOD. To confirm the preventive effect of UDCA on VOD, we conducted a prospective, unblinded randomized, multicenter study of UDCA involving 132 patients who underwent stern cell transplantation for a variety of disorders. Sixty-seven patients were assigned to the UDCA-treated group, and 65 patients were assigned to the control group. The clinical characteristics of the two groups were similar with respect to primary diagnosis, age, sex, and baseline organ function. The preparative regimen and GVHD prophylaxis did not differ significantly between the two groups. UDCA was highly effective in preventing VOD, which occurred in only 3.0{\%} in the UDCA-treated group, as opposed to 18.5{\%} in the control group (P = 0.0043). There were no adverse effects attributable to UDCA. The initial promising report of a prophylactic effect of UDCA on VOD after stern cell transplantation was confirmed in this prospective study. (C) 2000 Wiley-Liss, Inc.",
keywords = "Hepatic VOD, Prophylaxis, Stem cell transplantation, Ursodeoxycholic acid (UDCA)",
author = "Kazuteru Ohashi and Juichi Tanabe and Reiko Watanabe and Takeshi Tanaka and Hisashi Sakamaki and Atsuo Maruta and Shinichiro Okamoto and Nobuyuki Aotsuka and Kenji Saito and Miki Nishimura and Hakumei Oh and Michio Matsuzaki and Satoshi Takahashi and Shuji Yonekura",
year = "2000",
doi = "10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N",
language = "English",
volume = "64",
pages = "32--38",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - The japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation

AU - Ohashi, Kazuteru

AU - Tanabe, Juichi

AU - Watanabe, Reiko

AU - Tanaka, Takeshi

AU - Sakamaki, Hisashi

AU - Maruta, Atsuo

AU - Okamoto, Shinichiro

AU - Aotsuka, Nobuyuki

AU - Saito, Kenji

AU - Nishimura, Miki

AU - Oh, Hakumei

AU - Matsuzaki, Michio

AU - Takahashi, Satoshi

AU - Yonekura, Shuji

PY - 2000

Y1 - 2000

N2 - Hepatic veno-occlusive disease (VOD) is a common transplant-related complication of stem cell transplantation. There is no safe and proven therapy for established VOD, and attempts have focused on its prevention. Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced the incidence of VOD. To confirm the preventive effect of UDCA on VOD, we conducted a prospective, unblinded randomized, multicenter study of UDCA involving 132 patients who underwent stern cell transplantation for a variety of disorders. Sixty-seven patients were assigned to the UDCA-treated group, and 65 patients were assigned to the control group. The clinical characteristics of the two groups were similar with respect to primary diagnosis, age, sex, and baseline organ function. The preparative regimen and GVHD prophylaxis did not differ significantly between the two groups. UDCA was highly effective in preventing VOD, which occurred in only 3.0% in the UDCA-treated group, as opposed to 18.5% in the control group (P = 0.0043). There were no adverse effects attributable to UDCA. The initial promising report of a prophylactic effect of UDCA on VOD after stern cell transplantation was confirmed in this prospective study. (C) 2000 Wiley-Liss, Inc.

AB - Hepatic veno-occlusive disease (VOD) is a common transplant-related complication of stem cell transplantation. There is no safe and proven therapy for established VOD, and attempts have focused on its prevention. Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced the incidence of VOD. To confirm the preventive effect of UDCA on VOD, we conducted a prospective, unblinded randomized, multicenter study of UDCA involving 132 patients who underwent stern cell transplantation for a variety of disorders. Sixty-seven patients were assigned to the UDCA-treated group, and 65 patients were assigned to the control group. The clinical characteristics of the two groups were similar with respect to primary diagnosis, age, sex, and baseline organ function. The preparative regimen and GVHD prophylaxis did not differ significantly between the two groups. UDCA was highly effective in preventing VOD, which occurred in only 3.0% in the UDCA-treated group, as opposed to 18.5% in the control group (P = 0.0043). There were no adverse effects attributable to UDCA. The initial promising report of a prophylactic effect of UDCA on VOD after stern cell transplantation was confirmed in this prospective study. (C) 2000 Wiley-Liss, Inc.

KW - Hepatic VOD

KW - Prophylaxis

KW - Stem cell transplantation

KW - Ursodeoxycholic acid (UDCA)

UR - http://www.scopus.com/inward/record.url?scp=0034093330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034093330&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N

DO - 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N

M3 - Article

C2 - 10815785

AN - SCOPUS:0034093330

VL - 64

SP - 32

EP - 38

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -